Cabaletta End Period Cash Flow from 2010 to 2024

CABA Stock  USD 2.34  0.02  0.85%   
Cabaletta Bio's End Period Cash Flow is increasing over the years with slightly volatile fluctuation. End Period Cash Flow is expected to dwindle to about 104.9 M. From 2010 to 2024 Cabaletta Bio End Period Cash Flow quarterly data regression line had arithmetic mean of  51,509,598 and r-squared of  0.69. View All Fundamentals
 
End Period Cash Flow  
First Reported
2018-06-30
Previous Quarter
178.6 M
Current Value
170.6 M
Quarterly Volatility
48.4 M
 
Covid
Check Cabaletta Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cabaletta Bio's main balance sheet or income statement drivers, such as Interest Expense of 1.4 M, Selling General Administrative of 10.9 M or Research Development of 58.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0241 or PTB Ratio of 4.13. Cabaletta financial statements analysis is a perfect complement when working with Cabaletta Bio Valuation or Volatility modules.
  
Check out the analysis of Cabaletta Bio Correlation against competitors.
For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.

Latest Cabaletta Bio's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Cabaletta Bio over the last few years. It is Cabaletta Bio's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cabaletta Bio's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Cabaletta End Period Cash Flow Regression Statistics

Arithmetic Mean51,509,598
Geometric Mean6,267
Coefficient Of Variation127.18
Mean Deviation57,409,249
Median1.33
Standard Deviation65,508,682
Sample Variance4291.4T
Range193.2M
R-Value0.83
Mean Square Error1444.6T
R-Squared0.69
Significance0.0001
Slope12,144,827
Total Sum of Squares60079.4T

Cabaletta End Period Cash Flow History

2024104.9 M
2023193.2 M
202281.6 M
2021122.2 M
2020101.4 M
2019136.2 M
201833 M

About Cabaletta Bio Financial Statements

Cabaletta Bio stakeholders use historical fundamental indicators, such as Cabaletta Bio's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Cabaletta Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cabaletta Bio's assets and liabilities are reflected in the revenues and expenses on Cabaletta Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cabaletta Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow193.2 M104.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cabaletta Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cabaletta Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cabaletta Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cabaletta Bio Stock:
Check out the analysis of Cabaletta Bio Correlation against competitors.
For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cabaletta Bio. If investors know Cabaletta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cabaletta Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.16)
Return On Assets
(0.31)
Return On Equity
(0.48)
The market value of Cabaletta Bio is measured differently than its book value, which is the value of Cabaletta that is recorded on the company's balance sheet. Investors also form their own opinion of Cabaletta Bio's value that differs from its market value or its book value, called intrinsic value, which is Cabaletta Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cabaletta Bio's market value can be influenced by many factors that don't directly affect Cabaletta Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cabaletta Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cabaletta Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cabaletta Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.